AstraZeneca slides even as the company’s coronavirus vaccine trial results show ‘promise’
AstraZeneca shares slid on Monday despite positive news from the drugmaker’s first human trials of an experimental COVID-19 vaccine.
In the early-stage trial of the vaccine, which is being developed in conjunction with Oxford University, healthy volunteers generated immune responses.
In early US trading, the company’s stock was down by about 2.7%.
Watch AstraZeneca trade live on Markets Insider.
Visit Business Insider’s homepage for more stories.
US weekly jobless claims hit 1.3 million, slightly exceeding economist forecastsGlobal consumer confidence posted a record plunge in the 2nd quarter as the coronavirus pandemic slammed job prospects, financesBANK OF AMERICA: Buy these 7 pharma stocks now as they race to develop COVID-19 treatments and vaccines
Original Source: feedproxy.google.com
Visited 200 Times, 1 Visit today